

Syngene

Syngene International Limited
Biocon Park SEZ, Bommasandra IV Phase,
Jigani Link Road, Bangalore 560 099, India.
T +91 80 2808 2808
F +91 80 4014 3150 / 2852 3423
CIN No. L85110KA1993PLC014937

www.syngeneintl.com

Ref: Syn/Acts/CS/SE/PR/BSE/NSE

December 13, 2016

To, The Manager Listing National Stock Exchange of India Limited Corporate Communication Department Bandra (East) Mumbai 500 051 Scrip Symbol : SYNGENE	To, The Manager Listing BSE Limited Corporate Relationship Department Dalal Street, Mumbai – 400 001 Scrip Code : 539268
---	--

Dear Sir/Madam,

Sub: Press Release

This has reference to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Please find enclosed the Press Release titled “**Fire Incident at Syngene Facility**”.

The above mentioned press release will also be available on website of the Company at www.syngeneintl.com.

This is for your information and records.

Thanking you.

Yours faithfully

For **SYNGENE INTERNATIONAL LIMITED**

Mayank Verma

Mayank Verma
Company Secretary

E mail: Mayank.verma@syngeneintl.com

M: +91 9739904949

T: 080 67758781



For Immediate Release

Fire Incident at Syngene Facility

No Injuries or Loss of Life; BCP activated to minimize impact on Operations

Bangalore, 13th December, 2016

Syngene International Ltd. informed that there was a fire incident yesterday evening at one of its research facilities at Biocon Park in Bangalore. This triggered the fire alarm and Syngene's Emergency Response Team (ERT) immediately got into action to evacuate the building. The fire department was called in and the fire was brought under control. There was no injury or loss of life due to this incident.

This research facility, including office and lab spaces, makes up approximately 10% of Syngene's total infrastructure at Biocon Park. The cause of the fire and the extent of damage to this lab facility is being assessed.

The company has implemented its Business Continuity Plan (BCP) to minimize impact on operations. Further, Syngene's Industrial All Risk Insurance Policy will help minimize the financial impact on account of damage to assets and loss of profits.

The company further added that all its other facilities within the same campus were unaffected due to this incident and continue to operate normally.

About Syngene

Syngene International Limited, (**BSE code: 539268, NSE Id: SYNGENE, ISIN Id: INE398R01022**) is one of Asia's largest Contract Research Organizations. It provides discovery and developmental services for new molecular entities across multiple platforms including Small Molecules, Large Molecules, Antibody-Drug Conjugates and Oligonucleotides. These services are aimed towards bringing novel molecules to the market by supporting the R&D efforts of organizations across diverse sectors like pharma, biotechnology, nutrition and animal health. Syngene offers an integrated platform for R&D focussed organizations to optimize their R&D investments and develop their novel molecules with a distinctive cost advantage. In FY2016, Syngene serviced 256 clients including 8 of the top 10 global pharma companies. For more details, visit: www.syngeneintl.com

For further information please reach out to:

Investor Contact	Media Contact
Chanderlekha Nayar P: +91 80 6775 8821 M: +91 7259192001	Sandeep Nair P: +91 80 6775 8775 M: +91 88843 67776

Syngene

Putting Science to Work

Confidentiality

Quality

Innovation

Science

PRESS RELEASE

13/12/2016

Fax: +91 80 2852 3423

E: chanderlekha.nayar@syngeneintl.com

Fax: +91 80 2852 3423

E: sandeep.nair@syngeneintl.com